Characteristics of “super responders” and “super nonresponders” to first biologic monotherapy for psoriasis: a nested case-control study
BJD, 2023.
Kayleigh J. Mason, Oras A. Alabas, Nick Dand, Richard B. Warren, Nick J. Reynolds, Jonathan N.W.N. Barker, Zenas Z. N. Yiu, Catherine H. Smith, Christopher E.M. Griffiths, the BADBIR Study Group.
Read publication: BJD
Related
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study...
Uptake of tumour necrosis factor - alpha inhibitor biosimilars for psoriasis: A drug utilisation stu...
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective c...
0 Comments